← Back to headlines
Jefferies Reduces Upside for Arbutus Biopharma
Jefferies has lowered its upside potential assessment for Arbutus Biopharma Corporation, citing a higher probability of appeal.
17 Apr, 13:58 — 17 Apr, 13:58
Sources
Showing 1 of 1 sources
Related Stories
Treasury Secretary Bessent's Bond Strategy Faces Scrutiny and Criticism
8h ago
Analysts Assess NVIDIA's Valuation and Volatility Risks Following Weekly Stock Decline
10h ago
Richtech Robotics Announces Stock Repurchase Program, Shares Rise
12h ago
Apollo, KKR, and IFM Investors Finalists in AB Ports Stake Sale
12h ago